Centrexion Therapeutics stock hits 52-week low at $0.55

Published 29/05/2025, 20:16
Centrexion Therapeutics stock hits 52-week low at $0.55

In a challenging year for Centrexion Therapeutics Corp, the biopharmaceutical company’s stock has tumbled to a 52-week low, touching down at $0.55. Despite the current market pressure, InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 48.8 and more cash than debt on its balance sheet. This latest price level reflects a significant downturn for the company, which has seen its stock value decrease by 68.55% over the past year. With a market capitalization of $55.35 million, investors have been closely monitoring Centrexion as it navigates through a period marked by volatility and uncertainty within the biotech sector. The 52-week low serves as a critical indicator of the company’s recent performance and market sentiment, as stakeholders consider the implications of this substantial year-over-year change. According to InvestingPro, analyst price targets range from $4 to $9, suggesting potential upside from current levels. Discover 10 more exclusive insights about CNTX with an InvestingPro subscription.

In other recent news, Context Therapeutics announced promising preclinical data for its cancer treatment, CT-95, at the American Association for Cancer Research Annual Meeting. The treatment targets mesothelin-expressing cancers, such as pancreatic and ovarian cancers, and has initiated a Phase 1 clinical trial in the United States. The company expects to release initial clinical data by mid-2026. Meanwhile, William Blair has started coverage on Context Therapeutics with an Outperform rating, citing the potential of the company’s T-cell engagers. This endorsement reflects confidence in the company’s ongoing trials and its potential to succeed in the innovative space of cancer therapies. Additionally, JMP Securities has reaffirmed a Market Outperform rating for Context Therapeutics, maintaining a $4.00 price target. The company ended 2024 with $94.4 million in cash, supporting its operations through multiple clinical readouts. Context Therapeutics recently appointed Dr. Karen Smith as interim Chief Medical (TASE:BLWV) Officer, bringing over two decades of industry experience to the role.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.